Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Copyright © 2015 Elsevier B.V. All rights reserved..
Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (TB) reactivation in patients with latent tuberculosis infection (LTBI) has been recorded for anti-TNF agents, while a low or absent risk is associated with the non-anti-TNF targeted biologics. To reduce this risk several recommendation sets have been published over time, but in most of them the host-related risk, and the predisposing role to TB reactivation exerted by corticosteroids and by the traditional disease-modifying anti-rheumatic drugs has not been adequately addressed. Moreover, the management of the underlying disease, and the timing of biologic restarting in patients with TB occurrence have been rarely indicated. A multidisciplinary expert panel, the Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy (SAFEBIO), was constituted, and through a review of the literature, an evidence-based guidance for LTBI detection, identification of the individualized level of risk of TB reactivation, and practical management of patients with TB occurrence was formulated. The literature review confirmed a higher TB risk associated with monoclonal anti-TNF agents, a low risk for soluble receptor etanercept, and a low or absent risk for non-anti-TNF targeted biologics. Considering the TB reactivation risk associated with host demographic and clinical features, and previous or current non-biologic therapies, a low, intermediate, or high TB reactivation risk in the single patient was identified, thus driving the safest biologic choice. Moreover, based on the underlying disease activity measurement and the different TB risk associated with non-biologic and biologic therapies, practical indications for the treatment of RA, PsA, AS, and Pso in patients with TB occurrence, as well as the safest timing of biologic restarting, were provided.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 14(2015), 6 vom: 01. Juni, Seite 503-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cantini, Fabrizio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ankylosing spondylitis |
|---|
| Anmerkungen: |
Date Completed 17.08.2015 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2015.01.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM245622225 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM245622225 | ||
| 003 | DE-627 | ||
| 005 | 20231224141256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2015.01.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0818.xml |
| 035 | |a (DE-627)NLM245622225 | ||
| 035 | |a (NLM)25617816 | ||
| 035 | |a (PII)S1568-9972(15)00026-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2015 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier B.V. All rights reserved. | ||
| 520 | |a Since the introduction of biologics for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (Pso) an increased risk of tuberculosis (TB) reactivation in patients with latent tuberculosis infection (LTBI) has been recorded for anti-TNF agents, while a low or absent risk is associated with the non-anti-TNF targeted biologics. To reduce this risk several recommendation sets have been published over time, but in most of them the host-related risk, and the predisposing role to TB reactivation exerted by corticosteroids and by the traditional disease-modifying anti-rheumatic drugs has not been adequately addressed. Moreover, the management of the underlying disease, and the timing of biologic restarting in patients with TB occurrence have been rarely indicated. A multidisciplinary expert panel, the Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy (SAFEBIO), was constituted, and through a review of the literature, an evidence-based guidance for LTBI detection, identification of the individualized level of risk of TB reactivation, and practical management of patients with TB occurrence was formulated. The literature review confirmed a higher TB risk associated with monoclonal anti-TNF agents, a low risk for soluble receptor etanercept, and a low or absent risk for non-anti-TNF targeted biologics. Considering the TB reactivation risk associated with host demographic and clinical features, and previous or current non-biologic therapies, a low, intermediate, or high TB reactivation risk in the single patient was identified, thus driving the safest biologic choice. Moreover, based on the underlying disease activity measurement and the different TB risk associated with non-biologic and biologic therapies, practical indications for the treatment of RA, PsA, AS, and Pso in patients with TB occurrence, as well as the safest timing of biologic restarting, were provided | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ankylosing spondylitis | |
| 650 | 4 | |a Biologics | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Psoriatic arthritis | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Tuberculosis | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Nannini, Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Niccoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Florenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Delogu, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Garlaschi, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Sanduzzi, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Matucci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Prignano, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Conversano, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 700 | 0 | |a SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 14(2015), 6 vom: 01. Juni, Seite 503-9 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2015 |g number:6 |g day:01 |g month:06 |g pages:503-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2015.01.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2015 |e 6 |b 01 |c 06 |h 503-9 | ||